BioXcel Therapeutics Inc.

AI Score

0

Unlock

3.81
1.65 (76.39%)
At close: Mar 03, 2025, 3:59 PM
3.60
-5.51%
After-hours: Mar 03, 2025, 07:39 PM EST
No 1D chart data available
Bid 3.6
Market Cap 11.82M
Revenue (ttm) 166.54K
Net Income (ttm) -5.2M
EPS (ttm) -32.64
PE Ratio (ttm) -0.12
Forward PE -0.3
Analyst Hold
Ask 3.63
Volume 146,173,397
Avg. Volume (20D) 1,914,585
Open 2.37
Previous Close 2.16
Day's Range 2.37 - 6.81
52-Week Range 1.72 - 52.80
Beta -0.01

About BTAI

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 74
Stock Exchange NASDAQ
Ticker Symbol BTAI
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for BTAI stock is "Hold." The 12-month stock price forecast is $32, which is an increase of 739.90% from the latest price.

Buy 50.00%
Hold 25.00%
Sell 25.00%
Stock Forecasts

Next Earnings Release

BioXcel Therapeutics Inc. is scheduled to release its earnings on Mar 14, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
20 hours ago
BioXcel Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
3 days ago
+24.86%
BioXcel Therapeutics shares are trading higher after the company announced it regained Nasdaq listing compliance.